FILTER BY:
Details
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Address: 5115 Centre Ave, Pittsburgh, PA 15232, USA
Phone: 877-451-7009
Mesothelioma Type:
- Pleural: False
- Peritoneal: True
- Pericardial: False
- Tunica Vaginalis: False
Type: Epitheliod, Biphasic, Sarcomatoid
Condition: Peritoneal Malignant Mesothelioma
Description: This phase II trial compares the usual treatment alone to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.
Research Center: University of Pittsburgh Cancer Institute (UPCI)
Treatment Interventions: BIOLOGICAL: Atezolizumab, BIOLOGICAL: Bevacizumab, PROCEDURE: Biospecimen Collection, DRUG: Carboplatin, PROCEDURE: Computed Tomography, PROCEDURE: Cytoreductive Surgery, DRUG: Pemetrexed, PROCEDURE: Positron Emission Tomography
Potential Impact: High
Clinical Trial Number: NCT05001880
Phase: Phase 2
Status: Recruiting
